Active substanceCocarboxylaseCocarboxylase
Similar drugsTo uncover
  • Cocarboxylase
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Cocarboxylase
    lyophilizate w / m 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase-Ferein
    lyophilizate w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cocarboxylase-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
  • Cocarboxylase hydrochloride
    lyophilizate w / m in / in 
  • Dosage form: & nbsp

    lyophilizate for the preparation of solution for intravenous and intramuscular administration

    Composition:

    One ampoule contains:

    Active substance:

    Cocarboxylase hydrochloride - 50 mg.

    Excipient:

    Sodium carbonate (sodium carbonate) 8 mg

    Description:Lyophilized powder or dry porous hygroscopic mass of white with a characteristic odor.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.11.D.A   Vitamin B1

    Pharmacodynamics:Cocarboxylase - coenzyme thiamine (vitamin B1), in the body phosphorylated to form mono-, di- and triphosphate esters, is part of the enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids, pyro-grape acid. Endogenous cocarboxylase is formed in the body from exogenous thiamin by phosphorylation, however, the properties of cocarboxylase do not fully correspond to the properties of thiamine and it can not be used for the prevention and treatment of hypo- and avitaminosis B1. Cocarboxylase improves the absorption of glucose, trophic tissue of the nervous system, contributes to the normalization of the function of the cardiovascular system. Reduces the level of lactic and pyruvic acids in the blood (increasing the content of these acids leads to the development of acidosis and acidosis).
    Indications:

    Kokarboksilazy appointed in the complex therapy of hepatic and renal failure, diabetic precoma and coma, diabetic ketoacidosis, chronic heart failure and heart rhythm disorders, peripheral neuritis.

    Children prescribe the drug for the same indications. In newborns, the drug is also used as part of complex therapy of conditions accompanied by hypoxia and acidosis, including asphyxia of newborns, hypoxic encephalopathy, circulatory insufficiency, pneumonia, sepsis.

    Contraindications:

    Hypersensitivity to the drug.

    Pregnancy and lactation:

    Data on the safety of the drug when it is used by pregnant women are not available. Due to the insufficient number of studies, the drug should not be given to pregnant and lactating women.

    Dosing and Administration:

    Kokarboksilazu injected intramuscularly or intravenously (struino or drip). The contents of the ampoule (50 mg) are dissolved immediately before injection into 2 ml of water for injection. With intravenous jet injection, the volume is adjusted to 10-20 ml, with dropwise administration - up to 200-400 ml, adding a 0.9% solution of sodium chloride or a 5% solution of dextrose (glucose).

    With violations of the heart rate: 100-200 mg per day for 15-30 days. In chronic heart failure: 50 mg 2 hours before the use of digitalis preparations 2-3 times a day.

    In diabetes (ketoacidosis, coma), the daily dose is 100 mg.

    In acute renal and hepatic insufficiency intravenously injected 100-150 mg 3 times a day or drip (previously dissolved in a 5% solution of dextrose (glucose)) for 100-150 mg per day.

    With peripheral neuritis, intramuscularly administered at a dose of 50-100 mg per day for 1-1.5 months.

    Children are given intramuscularly, intravenously (drip or jet). Depending on the severity of the condition and clinical symptoms, it is prescribed from 25 to 50 mg per day. The course of treatment is from 3-7 to 15-30 days. The newborn is injected intravenously (slowly) 10 mg per 1 kg of body weight once a day.

    Side effects:

    Allergic reactions are possible (hives, itchy skin); when intramuscular injection - hyperemia, itching, edema (at the injection site).

    Overdose:

    There is no information on overdose.

    Interaction:

    Kokarboksilaza increases the cardiotonic action of cardiac glycosides and improves their tolerability.

    Special instructions:

    Without features.

    Effect on the ability to drive transp. cf. and fur:

    The effect of the drug on the ability to drive vehicles and mechanisms has not been studied.

    Form release / dosage:

    Lyophilizate for the preparation of a solution for intravenous and intramuscular injection of 50 mg in ampoules.

    Packaging:

    For 10 ampoules with instructions for use, with an ampoule or ampoule ampoule knife in a pack or box of cardboard.

    5 ampoules with the preparation complete with 5 ampoules of water for injections of 2 ml with the instruction for use, with a knife ampoule or scarifier ampullum in a pack or box of cardboard.

    5 ampoules with the preparation and 5 ampoules with water for injections of 2 ml in separate contour cell packs. 1 contour cell package with the preparation and 1 contour cell pack with water for injection with instructions for use, with a vial ampoule or ampoule knife in a pack of cardboard.

    When packaging ampoules that have a break ring or an opening point, the ampoule knife or the ampoule scapegrator is not put in.

    5 ampoules with the preparation and 5 ampoules with water for injection of 2 ml in separate cassette contour packs. 1 cassette contour pack with the preparation and 1 cassette contour pack with water for injection with instructions for use in a pack of cardboard.

    Storage conditions:

    Store in a dark place at a temperature of no higher than 20 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N001256 / 01
    Date of registration:27.12.2007 / 19.09.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:MICROGEN FGUP Scientific and Production Association MICROGEN FGUP Scientific and Production Association Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.01.2018
    Illustrated instructions
      Instructions
      Up